Treating Prehypertension
To the Editor: The study by Julius et al. of the efficacy of candesartan for prehypertension (April 20 issue) 1 demonstrates what seemed obvious: if patients with prehypertension receive hypotensive drugs, arterial hypertension will develop in fewer of them because they are already being treated. Th...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2006-07, Vol.355 (4), p.416-418 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 418 |
|---|---|
| container_issue | 4 |
| container_start_page | 416 |
| container_title | The New England journal of medicine |
| container_volume | 355 |
| creator | Grassi, Daniel G |
| description | To the Editor:
The study by Julius et al. of the efficacy of candesartan for prehypertension (April 20 issue)
1
demonstrates what seemed obvious: if patients with prehypertension receive hypotensive drugs, arterial hypertension will develop in fewer of them because they are already being treated. This prediction was borne out in the study, but as compared with placebo, candesartan did not reduce cardiovascular events during the study period.
The question is, does the administration of a hypotensive drug at a fixed dose reduce the cardiovascular morbidity and mortality in patients with prehypertension, as compared with the use of nonpharmacologic treatment and . . . |
| doi_str_mv | 10.1056/NEJMc061382 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68677566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68677566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-56728c42dfdbd109a68a9ec7a9a497c9dc09b4975b77a52518822b9dbf38fbc53</originalsourceid><addsrcrecordid>eNqN0DtPwzAUBWALgWgpTCxMCAmJBQWu3_ZYVeWl8hjKbNmOA6mapNjJ0H9PUCvBwNC7nDt8OsNB6BTDDQYubl-mT88eBKaK7KEh5pRmjIHYR0MAojImNR2go5QW0B9m-hANsFASNKFDdDaPwbZl_XHxFsPnehViG-pUNvUxOijsMoWTbY7Q-910PnnIZq_3j5PxLPNMsTbjQhLlGcmL3OUYtBXK6uCl1ZZp6XXuQbv-405KywnHShHidO4KqgrnOR2hq03vKjZfXUitqcrkw3Jp69B0yQglpORC7AaJ3A0KAtDD6w30sUkphsKsYlnZuDYYzM-05s-0vT7f1nauCvmv3W7Zg8sNqKpk6rCo_q35BmyGfGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68676200</pqid></control><display><type>article</type><title>Treating Prehypertension</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Grassi, Daniel G</creator><creatorcontrib>Grassi, Daniel G</creatorcontrib><description>To the Editor:
The study by Julius et al. of the efficacy of candesartan for prehypertension (April 20 issue)
1
demonstrates what seemed obvious: if patients with prehypertension receive hypotensive drugs, arterial hypertension will develop in fewer of them because they are already being treated. This prediction was borne out in the study, but as compared with placebo, candesartan did not reduce cardiovascular events during the study period.
The question is, does the administration of a hypotensive drug at a fixed dose reduce the cardiovascular morbidity and mortality in patients with prehypertension, as compared with the use of nonpharmacologic treatment and . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc061382</identifier><identifier>PMID: 16870923</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Antihypertensive Agents - therapeutic use ; Benzimidazoles - therapeutic use ; Biphenyl Compounds - therapeutic use ; Cardiovascular Diseases - prevention & control ; Humans ; Hypertension - prevention & control ; Risk ; Tetrazoles - therapeutic use</subject><ispartof>The New England journal of medicine, 2006-07, Vol.355 (4), p.416-418</ispartof><rights>Copyright © 2006 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-56728c42dfdbd109a68a9ec7a9a497c9dc09b4975b77a52518822b9dbf38fbc53</citedby><cites>FETCH-LOGICAL-c484t-56728c42dfdbd109a68a9ec7a9a497c9dc09b4975b77a52518822b9dbf38fbc53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc061382$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc061382$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16870923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grassi, Daniel G</creatorcontrib><title>Treating Prehypertension</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
The study by Julius et al. of the efficacy of candesartan for prehypertension (April 20 issue)
1
demonstrates what seemed obvious: if patients with prehypertension receive hypotensive drugs, arterial hypertension will develop in fewer of them because they are already being treated. This prediction was borne out in the study, but as compared with placebo, candesartan did not reduce cardiovascular events during the study period.
The question is, does the administration of a hypotensive drug at a fixed dose reduce the cardiovascular morbidity and mortality in patients with prehypertension, as compared with the use of nonpharmacologic treatment and . . .</description><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Biphenyl Compounds - therapeutic use</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Humans</subject><subject>Hypertension - prevention & control</subject><subject>Risk</subject><subject>Tetrazoles - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0DtPwzAUBWALgWgpTCxMCAmJBQWu3_ZYVeWl8hjKbNmOA6mapNjJ0H9PUCvBwNC7nDt8OsNB6BTDDQYubl-mT88eBKaK7KEh5pRmjIHYR0MAojImNR2go5QW0B9m-hANsFASNKFDdDaPwbZl_XHxFsPnehViG-pUNvUxOijsMoWTbY7Q-910PnnIZq_3j5PxLPNMsTbjQhLlGcmL3OUYtBXK6uCl1ZZp6XXuQbv-405KywnHShHidO4KqgrnOR2hq03vKjZfXUitqcrkw3Jp69B0yQglpORC7AaJ3A0KAtDD6w30sUkphsKsYlnZuDYYzM-05s-0vT7f1nauCvmv3W7Zg8sNqKpk6rCo_q35BmyGfGw</recordid><startdate>20060727</startdate><enddate>20060727</enddate><creator>Grassi, Daniel G</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060727</creationdate><title>Treating Prehypertension</title><author>Grassi, Daniel G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-56728c42dfdbd109a68a9ec7a9a497c9dc09b4975b77a52518822b9dbf38fbc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Biphenyl Compounds - therapeutic use</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Humans</topic><topic>Hypertension - prevention & control</topic><topic>Risk</topic><topic>Tetrazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grassi, Daniel G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grassi, Daniel G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treating Prehypertension</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2006-07-27</date><risdate>2006</risdate><volume>355</volume><issue>4</issue><spage>416</spage><epage>418</epage><pages>416-418</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
The study by Julius et al. of the efficacy of candesartan for prehypertension (April 20 issue)
1
demonstrates what seemed obvious: if patients with prehypertension receive hypotensive drugs, arterial hypertension will develop in fewer of them because they are already being treated. This prediction was borne out in the study, but as compared with placebo, candesartan did not reduce cardiovascular events during the study period.
The question is, does the administration of a hypotensive drug at a fixed dose reduce the cardiovascular morbidity and mortality in patients with prehypertension, as compared with the use of nonpharmacologic treatment and . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>16870923</pmid><doi>10.1056/NEJMc061382</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2006-07, Vol.355 (4), p.416-418 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68677566 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Angiotensin II Type 1 Receptor Blockers - therapeutic use Antihypertensive Agents - therapeutic use Benzimidazoles - therapeutic use Biphenyl Compounds - therapeutic use Cardiovascular Diseases - prevention & control Humans Hypertension - prevention & control Risk Tetrazoles - therapeutic use |
| title | Treating Prehypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A39%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treating%20Prehypertension&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Grassi,%20Daniel%20G&rft.date=2006-07-27&rft.volume=355&rft.issue=4&rft.spage=416&rft.epage=418&rft.pages=416-418&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc061382&rft_dat=%3Cproquest_cross%3E68677566%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68676200&rft_id=info:pmid/16870923&rfr_iscdi=true |